6 MARCH 2024
Oncimmune Holdings plc
("Oncimmune" or the "Company")
Posting of Notice of General Meeting
Oncimmune Holdings plc (AIM: ONC.L), a leading autoantibody profiling company to the pharmaceutical and biotechnology industry enabling precision medicine, announces that it has sent a notice of a General Meeting ("GM") to shareholders, to be held at 10:00am GMT on 2 April 2024 at the offices of Singer Capital Markets, 1 Bartholomew Lane, London, EC2N 2AX. The principal purpose of the GM will be to approve the Company's Annual Report and Accounts for the financial year ended 31 August 2023 ("Annual Report") which was published on 29 February 2024. The Annual Report and the notice of GM can be viewed on the "Investors" section of the Company's website at www.oncimmune.com.
For further information:
Oncimmune Holdings plc
contact@oncimmune.com
Singer Capital Markets (Nominated Adviser and Broker)
Philip Davies, Harry Gooden, James Fischer
+44 (0)20 7496 3000
Zeus (Joint Broker)
Dominic King, Victoria Ayton, Dan Bate
+44 (0)20 3829 5000
+44 (0)20 3727 1000
About Oncimmune
Oncimmune is a precision medicine company, specialising in analysing immune interactions through the autoantibody profile. Taking a platform approach to generating insights, Oncimmune is partnering with global pharmaceutical and biotech companies, as well as contract research organisations (CROs) to discover novel biomarkers for the development of more targeted and effective therapies across many immune-mediated diseases. Our mission at Oncimmune is to enable precision medicine. We help our partners to discover novel biomarkers, drug targets and predict treatment efficacy through the application of our platform. We are able to do this by deploying our world class scientific team and our cutting-edge technology platform, built on years of experience in the field. Our aim is to make this an essential tool in drug discovery and development.
Oncimmune is headquartered in the UK, with its discovery and development facility based in Dortmund, Germany and a business development team based in the US and Europe.
For more information, visit www.oncimmune.com
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
